KR20230132887A - 플라비바이러스를 개선된 제제로 안정화시키는 조성물 및 방법 - Google Patents

플라비바이러스를 개선된 제제로 안정화시키는 조성물 및 방법 Download PDF

Info

Publication number
KR20230132887A
KR20230132887A KR1020237030300A KR20237030300A KR20230132887A KR 20230132887 A KR20230132887 A KR 20230132887A KR 1020237030300 A KR1020237030300 A KR 1020237030300A KR 20237030300 A KR20237030300 A KR 20237030300A KR 20230132887 A KR20230132887 A KR 20230132887A
Authority
KR
South Korea
Prior art keywords
composition
dengue
virus
trehalose
concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020237030300A
Other languages
English (en)
Korean (ko)
Inventor
질 앤 리벤굿
린다 마리 스트레인지
스티븐 마이클 에브
Original Assignee
다케다 백신즈 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 다케다 백신즈 인코포레이티드 filed Critical 다케다 백신즈 인코포레이티드
Publication of KR20230132887A publication Critical patent/KR20230132887A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
KR1020237030300A 2016-08-03 2017-08-03 플라비바이러스를 개선된 제제로 안정화시키는 조성물 및 방법 Withdrawn KR20230132887A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662370611P 2016-08-03 2016-08-03
US62/370,611 2016-08-03
PCT/US2017/045375 WO2018027075A1 (en) 2016-08-03 2017-08-03 Compositions and methods for stabilizing flaviviruses with improved formulations
KR1020197005623A KR102576789B1 (ko) 2016-08-03 2017-08-03 플라비바이러스를 개선된 제제로 안정화시키는 조성물 및 방법

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020197005623A Division KR102576789B1 (ko) 2016-08-03 2017-08-03 플라비바이러스를 개선된 제제로 안정화시키는 조성물 및 방법

Publications (1)

Publication Number Publication Date
KR20230132887A true KR20230132887A (ko) 2023-09-18

Family

ID=59593235

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020237030300A Withdrawn KR20230132887A (ko) 2016-08-03 2017-08-03 플라비바이러스를 개선된 제제로 안정화시키는 조성물 및 방법
KR1020197005623A Active KR102576789B1 (ko) 2016-08-03 2017-08-03 플라비바이러스를 개선된 제제로 안정화시키는 조성물 및 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020197005623A Active KR102576789B1 (ko) 2016-08-03 2017-08-03 플라비바이러스를 개선된 제제로 안정화시키는 조성물 및 방법

Country Status (13)

Country Link
US (3) US10835597B2 (https=)
EP (1) EP3493839A1 (https=)
JP (2) JP7280179B2 (https=)
KR (2) KR20230132887A (https=)
CN (1) CN109789200A (https=)
AU (2) AU2017305498B2 (https=)
CA (1) CA3030343A1 (https=)
CO (1) CO2019001448A2 (https=)
MX (2) MX2019001473A (https=)
PH (1) PH12019500003A1 (https=)
SG (2) SG11201811831SA (https=)
TW (2) TW202309276A (https=)
WO (1) WO2018027075A1 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104984357B (zh) * 2015-06-02 2018-01-30 长春百克生物科技股份公司 不含明胶的疫苗保护剂组合物及流感减毒活疫苗
CR20190291A (es) * 2016-12-23 2019-11-05 Serum Institute Of India Pvt Ltd Métodos mejorados para estimular la productividad de anticuerpos en el cultivo de células de mamiferos y reducir la agregación durante los procesos de formulación post-tratamiento (downstream) y formulaciones de anticuerpos estables obtenidas a partir de los mismos
WO2019112921A1 (en) 2017-12-07 2019-06-13 Merck Sharp & Dohme Corp. Formulations of dengue virus vaccine compositions
CA3094404A1 (en) * 2018-03-20 2019-09-26 National Research Council Of Canada A method for lyophilizing live vaccine strains of francisella tularensis
KR102646145B1 (ko) 2018-05-31 2024-03-11 주식회사 엑소코바이오 줄기세포 유래의 엑소좀을 유효성분으로 포함하는 모공 축소용 조성물
KR102058961B1 (ko) 2018-07-28 2019-12-24 주식회사 엑소코바이오 엑소좀의 동결건조 방법
KR102163806B1 (ko) 2018-07-30 2020-10-07 주식회사 엑소코바이오 줄기세포 유래의 엑소좀을 유효성분으로 포함하는 피지분비 감소용 조성물
US11464815B2 (en) * 2018-09-05 2022-10-11 Takeda Vaccines, Inc. Dengue vaccine unit dose and administration thereof
KR20210100662A (ko) * 2018-12-05 2021-08-17 세레스 테라퓨틱스, 인코포레이티드 박테리아를 안정화시키는 조성물 그리고 이의 용도
BR112022001476A2 (pt) 2019-08-16 2023-10-03 Takeda Vaccines Inc Uso de uma vacina contra hepatite a e uma composição de vacina contra dengue ou uma dose unitária de uma composição de vacina contra dengue, combinação de vacina e kit
BR112022015710A2 (pt) * 2020-02-27 2022-09-27 Takeda Vaccines Inc Método para remover dna de célula hospedeira a partir da preparação de vírus
CN115023135B (zh) * 2020-02-28 2024-04-19 台湾粒线体应用技术股份有限公司 线粒体的冷冻保存剂与使用其的线粒体冷冻保存方法
CN113549653B (zh) * 2020-04-23 2024-03-22 上海赛比曼生物科技有限公司 用于慢病毒载体长期存贮的组合试剂
CN111588859B (zh) * 2020-06-02 2021-09-03 成都可恩生物科技有限公司 一种冻干保护剂及其应用和冻干苗及其制备方法
CN112501024A (zh) * 2020-12-03 2021-03-16 英科新创（苏州）生物科技有限公司 一种体外诊断试剂盒通用型质控品保存液
EP4012025A1 (en) * 2020-12-10 2022-06-15 Univerzita Palackého v Olomouci Transport medium for samples containing nucleic acids and/or proteins
CN113730592B (zh) * 2021-09-03 2023-12-19 吉林正业生物制品股份有限公司 一种鸭坦布苏病毒病活疫苗冻干保护剂及制备方法和应用
EP4356925B1 (en) * 2022-10-18 2025-09-10 Takeda Vaccines, Inc. Dengue vaccine formulation
WO2025027616A1 (en) * 2023-08-01 2025-02-06 Serum Institute Of India Private Limited Freeze-dried viral vaccine compositions and method of manufacturing thereof
WO2025072259A1 (en) 2023-09-25 2025-04-03 Takeda Vaccines, Inc. Coadministration of tetravalent dengue vaccine with hpv vaccine
WO2025122946A1 (en) * 2023-12-07 2025-06-12 Rovin Richard A Zika viruses and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005066333A1 (en) * 2003-12-30 2005-07-21 Aventis Pasteur, Inc. Stabilizing compositions for recombinant viruses
MX2009004862A (es) * 2006-11-07 2009-07-17 Sanofi Pasteur Biologics Co Estabilizacion de vacunas por liofilizacion.
WO2009014774A1 (en) * 2007-04-06 2009-01-29 Inviragen, Inc. Methods and compositions for live attenuated viruses
EP2143440A1 (fr) * 2008-07-09 2010-01-13 Sanofi Pasteur Agent stabilisant et composition vaccinale comprenant un ou plusieurs flavivirus vivants atténués
CN104984357B (zh) * 2015-06-02 2018-01-30 长春百克生物科技股份公司 不含明胶的疫苗保护剂组合物及流感减毒活疫苗
JP2019511533A (ja) * 2016-04-13 2019-04-25 タケダ ワクチン, インコーポレイテッドTakeda Vaccines, Inc. 小児及び若年成人のデングウイルスに対するワクチンの組成物及び方法

Also Published As

Publication number Publication date
US20230263880A1 (en) 2023-08-24
BR112019001299A2 (pt) 2019-04-30
AU2017305498B2 (en) 2023-03-30
JP7280179B2 (ja) 2023-05-23
CN109789200A (zh) 2019-05-21
KR102576789B1 (ko) 2023-09-12
AU2017305498A1 (en) 2019-01-24
MX2019001473A (es) 2019-09-23
JP2019524771A (ja) 2019-09-05
US20190184004A1 (en) 2019-06-20
WO2018027075A1 (en) 2018-02-08
US10835597B2 (en) 2020-11-17
KR20190034598A (ko) 2019-04-02
CA3030343A1 (en) 2018-02-08
TW201807191A (zh) 2018-03-01
PH12019500003A1 (en) 2019-10-14
SG11201811831SA (en) 2019-01-30
JP2023052624A (ja) 2023-04-11
AU2023203715A1 (en) 2023-07-06
TWI766876B (zh) 2022-06-11
US11701421B2 (en) 2023-07-18
MX2022010907A (es) 2022-10-07
SG10201913040SA (en) 2020-03-30
CO2019001448A2 (es) 2019-04-30
EP3493839A1 (en) 2019-06-12
US20210121558A1 (en) 2021-04-29
TW202309276A (zh) 2023-03-01

Similar Documents

Publication Publication Date Title
KR102576789B1 (ko) 플라비바이러스를 개선된 제제로 안정화시키는 조성물 및 방법
US10335479B2 (en) Methods and compositions for stabilizing dried biological materials
Patel et al. Combined semi-empirical screening and design of experiments (DOE) approach to identify candidate formulations of a lyophilized live attenuated tetravalent viral vaccine candidate
US10806781B2 (en) Compositions and methods for live, attenuated alphavirus formulations
US10632184B2 (en) Compositions and methods for stabilizing alphaviruses with improved formulations
BR112019001299B1 (pt) Composições, usos, métodos e kits para estabilizar flavivírus com formulações aprimoradas
HK1220358B (en) Compositions and methods for live, attenuated alphavirus formulations

Legal Events

Date Code Title Description
A107 Divisional application of patent
A302 Request for accelerated examination
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

St.27 status event code: A-0-1-A10-A17-div-PA0104

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PA0302 Request for accelerated examination

St.27 status event code: A-1-2-D10-D16-exm-PA0302

St.27 status event code: A-1-2-D10-D17-exm-PA0302

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

PC1202 Submission of document of withdrawal before decision of registration

St.27 status event code: N-1-6-B10-B11-nap-PC1202